Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …

Secondary central nervous system (CNS) lymphoma (SCNSL) is defined by the involvement
of the CNS, either at the time of initial diagnosis of systemic lymphoma or in the setting of …

Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …

Purpose To develop and validate a risk score for relapse in the CNS in patients with diffuse
large B-cell lymphoma (DLBCL). Patients and Methods A total of 2,164 patients (18 to 80 …

Purpose Adult T-cell leukemia-lymphoma (ATL) is a distinct mature T-cell malignancy
caused by chronic infection with human T-lymphotropic virus type 1 with diverse clinical …

Prophylaxis is commonly used to prevent central nervous sy stem (CNS) relapse in diffuse
large B-cell lymphoma (DLBCL), with no clear standard of care. We retrospectively …

Dual expression of MYC and BCL2 by immunohistochemistry (IHC) is associated with poor
outcome in diffuse large B-cell lymphoma (DLBCL). Dual translocation of MYC and BCL2, so …

The 2016 revision of the World Health Organization (WHO) classification for lymphoma has
included a new category of lymphoma, separate from diffuse large B-cell lymphoma, termed …

Central nervous system (CNS) relapse affects 5% of diffuse large B‐cell lymphoma (DLBCL)
patients and portends a poor prognosis. Prophylactic intravenous high‐dose methotrexate …

Although methotrexate (MTX) is the most widely used therapy for central nervous system
(CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal …